ArticleCellular oncology (Dordrecht, Netherlands)2026
CXCL12 derived from cancer-associated fibroblasts mediates dysfunctional intratumoral adaptive immunity in diabetic pancreatic adenocarcinoma.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) affects the occurrence and progression of pancreatic adenocarcinoma (PAAD), but the DM-related immune characteristic in PAAD remains unclear. This study aimed to elucidate the immune landscape and underlying mechanism in diabetic PAAD.
methodsRNA-sequencing data from primary sorted cancer-associated fibroblasts (CAFs) and TCGA database were used to screen out differentially expressed genes (DEGs), and enrichment analyses were performed to identify key pathways. xCell, Timer, Estimate, Quantiseq, and MCPcounter algorithms were applied to assess intratumoral immune infiltration, which was meanwhile verified by multicolor immunofluorescence of clinical samples. In vitro experiments, including proliferation assay and immune phenotype identification, were carried out to confirm the impact of the key gene on immune reprogramming. An animal model of mixed injection of pancreatic stellate cells (PSCs) and pancreatic cancer cells was constructed to validate in vivo effects of involved pathway in diabetic pancreatic cancer.
resultsScreened DEGs were enriched in several immunomodulatory pathways. The immunity in diabetic pancreatic cancer was shown to be seemingly flourishing but functionally defective, characterized by CD22+ B cells and TIGIT+ CD8+ T cells. Correlation analyses indicated that CXCL12 was significantly associated with the abundance and immune phenotype transformation of B and CD8+ T cells, with consistent results across multiple algorithms. More CXCL12High CAFs were detected in diabetic PAAD patients and mice. Meanwhile, the treatment of CXCL12High PSCs promoted the immune-suppressive phenotype of B and CD8+ T cells in both in vitro and in vivo experiments, and the blockade of CXCL12–CXCR4 axis by plerixafor showed therapeutic effects in subcutaneous tumor models.
conclusionsOur results delineated a distinct immune-suppressive landscape mediated by CAF-derived CXCL12 in diabetic PAAD individuals, which may help guide treatment decisions and predict immunotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.